Informations générales (source: ClinicalTrials.gov)
PERCEPTION Trial Protocol: Comparison of Predictive and Prognostic Capacities of Neutrophil, Lymphocyte and Platelet Counts and Tumour-infiltrating Lymphocytes in Triple Negative Breast Cancer (PERCEPTION)
Observational
Centre Jean Perrin (Voir sur ClinicalTrials)
décembre 2019
octobre 2032
05 avril 2025
The PERCEPTION study aims to assess the correlation between blood cell counts
(Leucocytes, Neutrophils, Lymphocytes, Platelets, NLR (Neutrophil-to-Lymphocyte Ratio)
and PLR (Platelet-to-Lymphocyte Ratio)) and Tumor Infiltrating Lymphocytes (TILs), at
baseline and after surgery, for patients diagnosed with triple negative breast cancer. It
also aims to assess these circulating elements and circulating tumor DNA as predictive
factor of metastatic recurrence in triple negative breast cancer.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Centre Jean PERRIN - 63000 - Clermont-Ferrand - Please Select - France | Alexia GIRO | Contact (sur clinicalTrials) | |||
Critères
Femme
Inclusion Criteria:
- Female
- Age > 18 years
- Diagnosed with primitive, non-metastatic, histologically proved, triple negative
breast cancer
- Patient treated with chemotherapy, surgery and radiation therapy
- Patient able to understand the French language
- Patient affiliated to social security
- Obtaining signed written consent
- Female
- Age > 18 years
- Diagnosed with primitive, non-metastatic, histologically proved, triple negative
breast cancer
- Patient treated with chemotherapy, surgery and radiation therapy
- Patient able to understand the French language
- Patient affiliated to social security
- Obtaining signed written consent
- Male
- Unavailable tumoral samples before inclusion
- Unavailable blood test results at baseline, before inclusion